Epilepsy | Treatment Algorithms | Claims Data Analysis | US | 2018

Market Outlook

Epilepsy is a heterogeneous condition requiring individualized treatment. Neurologists consider many factors when selecting among the numerous first-, second-, and third-generation antiepileptic drugs (AEDs) currently available and must make adjustments throughout a patient’s disease course to achieve optimal seizure control. Understanding the evolving patient journey in epilepsy provides important context about the complex, saturated, and heavily generic market that developers of new AED brands will enter. Our Treatment Algorithms offering provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients.

Questions Answered

• What patient share do key therapies and brands garner by line of therapy in newly diagnosed epilepsy patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed epilepsy patients?
• How have Briviact, Vimpat, and other third-generation brands been integrated into the treatment algorithm?
• What proportion of newly diagnosed epilepsy patients receive drug therapy during our tracking period, and how quickly? What percentage of these patients progress to later lines of therapy during the tracking period?
• What percentage of epilepsy patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
• What are the product-level compliance and persistency rates among drug-treated patients with epilepsy?

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.

Geographies: United States.

Real-world data: Longitudinal patient-level claims data analysis.

Key drugs covered: Vimpat, Aptiom, Briviact, Fycompa, Lyrica, levetiracetam, lamotrigine, cabamazepine and oxcarbazepine, valproates, others.

Key analysis provided:

• Brand use across longitudinal patient sample.
• Newly diagnosed patient analysis.
• Treatment initiation and progression.
• Line of therapy analysis.
• Combination therapy analysis.
• Source of business for recently treated patients.
• Persistency and compliance analysis.
• Product-level patient flowcharts.